Monopar Therapeutics, Inc.

Bérangère Vasseur-Demarcy

Pierre Attali

The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.

Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

Growing community of inventors

Deuil la Barre, France

Bérangère Vasseur-Demarcy